VEGF polymorphisms are associated with severity of diabetic retinopathy

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 8, 2008, Pages 3611-3616

  Churchill, Amanda J ^a   Carter, James G ^a   Ramsden, Conor ^a   Turner, Steven J ^a   Yeung, Anna ^a   Brenchley, Paul E C ^b   Ray, David W ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; VASCULOTROPIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

5' UNTRANSLATED REGION; ADULT; AGED; ANGIOGENESIS; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DNA EXTRACTION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; RETINA MACULA AGE RELATED DEGENERATION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; INTRON; MIDDLE AGED;

5' UNTRANSLATED REGIONS; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; HAPLOTYPES; HUMANS; INTRONS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 49049101927     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-1383     Document Type: Article

References (34)

1. Jorge R, Costa RA, Comt DC, Cintra LP, Scott IU. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE Study). Retina. 2006;26:1006-1013.
2. Ng EWM, Adamis AP. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann N Y Acad Sci. 2006;1082:151-171.
3. Bates DO, Cui TG, Doughty JM, et al. VEGF(165)b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002;62:4123-4131.
4. Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia. 2005;48:2422-2427.
5. Awata T, Kurihara S, Takata N, et al. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem Biophys Res Commun. 2005;333:679-685.
6. Vannay A, Dunai G, Banyasz I, et al. Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity. Pediatr Res. 2005;57:396-398.
7. Al-Kateb H, Mirea L, Xie XL, Sun L, Bull SLB, Liu M. Multiple variants in vascular endothelial growth factor (VEGF) gene are risk factors for severe retinopathy in type I diabetes: the DCCT/EDIC genetics study. Diabetes. 2007;56:2161-2168.
8. Churchill AJ, Carter JG, Lovell HC, et al. VEGF polymorphisms are associated with neovascular age-related macular degeneration. Hum Mol Genet. 2006;15:2955-2961.
9. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
10. Box NF, Wyeth JR, Mayne CJ, O'Gorman LE, Martin NG, Sturm RA. Complete sequence and polymorphism study of the human TYRP1 gene encoding tyrosinase-related protein 1. Mamm Genome. 1998;9:50-53.
11. Powell B, Toomes C, Scott S, et al. Polymorphisms in OPA1 are associated with normal tension glaucoma. Mol Vis. 2003;9:460-464.
12. Runnebaum IB, Tong XW, Konig R, et al. P53-based blood-test for P53pin3 and risk for sporadic ovarian cancer. Lancet. 1995;345:994.
13. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth-factor - multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 1991;266:11947-11954.
14. SeattleSNPs. NHLBI Program for Genomic Applications. Seattle WA: University of Washington, Fred Hutchinson Cancer Research Center; 2005.
15. Ke XY, Cardon LR. Efficient selective screening of haplotype tag SNPs. Bioinformatics. 2003;19:287-288.
16. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003;73:1162-1169.
17. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68:978-989.
18. Uitenbroek DG. SISA Binomial. Southampton, UK; 1997.
19. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003;63:812-816.
20. Del Bo R, Scarlato M, Ghezzi S, et al. VEGF gene variability and type 1 diabetes: evidence for a protective role. Immunogenetics. 2006;58:107-112.
21. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet. 2003;34:383-394.
22. Rueda B, Gonzalez-Gay MA, Lopez-Nevot MA, et al. Analysis of vascular endothelial growth factor (VEGF) functional variants in rheumatoid arthritis. Hum Immunol. 2005;66:864-868.
23. Errera FIV, Canani LH, Silva MER, et al. Functional vascular endothelial growth factor -634>C SNP is associated with proliferative diabetic retinopathy: a case-control study in a Brazilian population of European ancestry. Diabetes Care. 2007;30:275-279.
24. Liinamaa MJ. Association of single nucleotide polymorphisms (SNPs) of VEGF gene with diabetic retinopathy., European Association for Vision and Eye Research Annual Congress. Portoroz, Slovenia; 2007:Poster 344.
25. Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes. 2004;53:861-864.
26. Watson CJ, Webb NJA, Bottomley MJ, Brenchley PEC. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000;12:1232-1235.
27. Haines JL, Schnetz-Boutaud N, Schmidt S, et al. Functional candidate genes in age-related macular degeneration: Significant association with VEGF, VLDLR, and LRP6. Invest Ophthalmol Vis Sci. 2006;47:329-335.
28. Transplorer Version, 1.4. Wolfenbüttel, Germany: BioBase; 2004.
29. Heinemeyer T, Wingender E, Reuter I, et al. Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res. 1998;26:362-367.
30. Morris JF, Hromas R, Rauscher FJ. Characterization of the DNA-binding properties of the myeloid zinc-finger protein Mzf1-2 independent DNA-binding domains recognize 2 DNA consensus sequences with a common G-rich core. Mol Cell Biol. 1994;14:1786-1795.
31. Cartegni L, Wang JH, Zhu ZW, Zhang MQ, Krainer AR. ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res. 2003;31:3568-3571.
32. Smith PJ, Zhang CL, Wang JH, Chew SL, Zhang MQ, Krainer AR. An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum Mol Genet. 2006;15:2490-2508.
33. Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 2002;51:1635-1639.
34. Cho Y, Ahn B, Kwon O, et al. Method for diagnosing diabetic retinopathy by single nucleotide polymorphism, DNA fragment thereof, and primer thereof. WIPO patent WO/2006/135117. December 21, 2006.